Efficacy and safety of intravenous peramivir versus oral oseltamivir in the treatment of influenza in children: A meta-analysis

Objective: To investigate the efficacy and safety of intravenous peramivir compared to oral oseltamivir for pediatric influenza by a method of meta-analysis. Methods: Clinical trials involving intravenous peramivir versus oral oseltamivir therapy in children with influenza were searched from six databases until July 2023. Data were processed using Stata 15.0 software. Results: Seven published articles were identified in this review. The combined results exhibited that the clinical effective rate in the peramivir group (76.09 %) was higher than that in the oseltamivir group (58.85 %) (RR= 1.12, 95 %CI: 1.01 similar to 1.24, P = 0.038). The incidence of adverse reactions in the peramivir group (13.31 %) was lower than that in the oseltamivir group (17.34 %) (RR= 0.77, 95 %CI: 0.61-0.96, P = 0.023). Compared with the oseltamivir group, the peramivir group had lower recovery time of body temperature (WMD= -19.81, 95 % CI: -27.58 similar to-12.04, P < 0.001). Conclusion: Compared with oral oseltamivir, intravenous peramivir has better efficacy and higher safety for pediatric influenza.